Catalyst Pharmaceuticals reported that no decision has yet been received from the FDA with respect to the company’s New Drug Application, or NDA, for Firdapse. The company reported that a contractor working on a web page unintentionally allowed a live screen to be seen that reflected that the possible approval of the company’s NDA had already been received. The company issued a release in order to clarify to the marketplace the status of its NDA.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.